Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2012年 / 2卷 / 01期
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [1] Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (05) : 1 - 11
  • [2] Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis
    Pagano, Gennaro
    Rengo, Giuseppe
    Pasqualetti, Giuseppe
    Femminella, Grazia Daniela
    Monzani, Fabio
    Ferrara, Nicola
    Tagliati, Michele
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (07) : 767 - 773
  • [3] Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis
    Kishi, Taro
    Matsunaga, Shinji
    Oya, Kazuto
    Nomura, Ikuo
    Ikuta, Toshikazu
    Iwata, Nakao
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (02) : 401 - 425
  • [4] Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    PLOS ONE, 2015, 10 (04):
  • [5] Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
    Meng, Yan-Hong
    Wang, Pan-Pan
    Song, Ya-Xue
    Wang, Jian-Hua
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (03) : 1611 - 1624
  • [6] Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials
    Dou, Kai-Xin
    Tan, Meng-Shan
    Tan, Chen-Chen
    Cao, Xi-Peng
    Hou, Xiao-He
    Guo, Qi-Hao
    Tan, Lan
    Mok, Vincent
    Yu, Jin-Tai
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [7] Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
    Dominik, Glinz
    Viktoria, Gloy L.
    Andreas, Monsch U.
    Reto, Kressig W.
    Chandni, Patel
    Alba, McCord Kimberly
    Zanfina, Ademi
    Yuki, Tomonaga
    Matthias, Schwenkglenks
    Heiner, Bucher C.
    Heike, Raatz
    SWISS MEDICAL WEEKLY, 2019, 149
  • [8] Cost-effectiveness of pharmacological therapies for people with Alzheimer's disease and other dementias: a systematic review and meta-analysis
    Huo, Zhaohua
    Lin, Jiaer
    Bat, Baker K. K.
    Chan, Tak Kit
    Yip, Benjamin H. K.
    Tsoi, Kelvin K. F.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [9] Cost-effectiveness of pharmacological therapies for people with Alzheimer’s disease and other dementias: a systematic review and meta-analysis
    Zhaohua Huo
    Jiaer Lin
    Baker K. K. Bat
    Tak Kit Chan
    Benjamin H. K. Yip
    Kelvin K. F. Tsoi
    Cost Effectiveness and Resource Allocation, 20
  • [10] Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
    Kai-Xin Dou
    Meng-Shan Tan
    Chen-Chen Tan
    Xi-Peng Cao
    Xiao-He Hou
    Qi-Hao Guo
    Lan Tan
    Vincent Mok
    Jin-Tai Yu
    Alzheimer's Research & Therapy, 10